Intravenous mycophenolate mofetil: Safety, tolerability, and pharmacokinetics

Mark D. Pescovitz, D. Conti, J. Dunn, T. Gonwa, P. Halloran, H. Sollinger, S. Tomlanovich, S. Weinstein, S. Inokuchi, B. Kiberd, D. Kittur, R. M. Merion, D. Norman, A. Shoker, R. Wilburn, A. J. Nicholls, S. Arterburn, E. Dumont

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

An intravenous (i.v.) formulation of mycophenolate mofetil (MMF; CellCept®, Roche Pharmaceuticals, Inc., Palo Alto, CA) that will enable its administration to patients unable to tolerate oral medication is available. Two separate studies, an open-labeled pharmacokinetic (PK) study and a double-blind safety study, were performed. Within 24 h after transplant, 153 (safety study) and 45 (PK study) first or second renal transplant recipients were started on i.v. MMF 1 g Q12h or placebo (used in the safety study only, 2:1 MMF:placebo), given over 2 h via a dedicated peripheral venous catheter. In the safety study, per os (p.o.) MMF (1 g Q12h) or placebo was administered, starting within 72 h after transplant, whereas in the PK study, p.o. MMF was started on the evening of day 5. Sequential blood samples obtained on study days 5 (i.v. MMF) and 6 (p.o. MMF) before and up to 12 h after the AM dose were analyzed for mycophenolic acid (MPA) and MPA glucuronide (MPAG) concentrations by high-performance liquid chromatography. The area under the concentration curve (AUC) was calculated using the linear trapezoidal rule. The MPA AUC0-12 was higher for i.v. MMF than p.o. MMF (40.8 ± 11.4 μg.h/mL vs. 32.9 ± 15, p < 0.001). There were no other significant PK differences for plasma MPA or MPAG. In the safety study (n = 98 i.v. MMF vs. n = 55 placebo), 11 patients (11%, i.v. MMF) and 4 patients (7%, placebo) discontinued their use of the drug because of an adverse event (AE). Overall, AEs were similar between i.v. MMF and placebo. Injection site phlebitis (4%) and thrombosis (4%) were observed only with i.v. MMF. MMF i.v. 1 g twice daily (b.i.d.) should provide efficacy at least equivalent to p.o. MMF without increased toxicity, and it provides an acceptable alternative dose form in the immediate period after transplant.

Original languageEnglish (US)
Pages (from-to)179-188
Number of pages10
JournalClinical Transplantation
Volume14
Issue number3
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Mycophenolic Acid
Pharmacokinetics
Placebos
Safety
Transplants
Phlebitis
Glucuronides
Drug-Related Side Effects and Adverse Reactions
Double-Blind Method
Area Under Curve
Thrombosis
Catheters
High Pressure Liquid Chromatography
Kidney
Injections
Pharmaceutical Preparations

Keywords

  • Intravenous (i.v.)
  • Kidney transplantation
  • Mycophenolate mofetil
  • Pharmacokinetics
  • Safety

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Pescovitz, M. D., Conti, D., Dunn, J., Gonwa, T., Halloran, P., Sollinger, H., ... Dumont, E. (2000). Intravenous mycophenolate mofetil: Safety, tolerability, and pharmacokinetics. Clinical Transplantation, 14(3), 179-188. https://doi.org/10.1034/j.1399-0012.2000.140301.x

Intravenous mycophenolate mofetil : Safety, tolerability, and pharmacokinetics. / Pescovitz, Mark D.; Conti, D.; Dunn, J.; Gonwa, T.; Halloran, P.; Sollinger, H.; Tomlanovich, S.; Weinstein, S.; Inokuchi, S.; Kiberd, B.; Kittur, D.; Merion, R. M.; Norman, D.; Shoker, A.; Wilburn, R.; Nicholls, A. J.; Arterburn, S.; Dumont, E.

In: Clinical Transplantation, Vol. 14, No. 3, 2000, p. 179-188.

Research output: Contribution to journalArticle

Pescovitz, MD, Conti, D, Dunn, J, Gonwa, T, Halloran, P, Sollinger, H, Tomlanovich, S, Weinstein, S, Inokuchi, S, Kiberd, B, Kittur, D, Merion, RM, Norman, D, Shoker, A, Wilburn, R, Nicholls, AJ, Arterburn, S & Dumont, E 2000, 'Intravenous mycophenolate mofetil: Safety, tolerability, and pharmacokinetics', Clinical Transplantation, vol. 14, no. 3, pp. 179-188. https://doi.org/10.1034/j.1399-0012.2000.140301.x
Pescovitz, Mark D. ; Conti, D. ; Dunn, J. ; Gonwa, T. ; Halloran, P. ; Sollinger, H. ; Tomlanovich, S. ; Weinstein, S. ; Inokuchi, S. ; Kiberd, B. ; Kittur, D. ; Merion, R. M. ; Norman, D. ; Shoker, A. ; Wilburn, R. ; Nicholls, A. J. ; Arterburn, S. ; Dumont, E. / Intravenous mycophenolate mofetil : Safety, tolerability, and pharmacokinetics. In: Clinical Transplantation. 2000 ; Vol. 14, No. 3. pp. 179-188.
@article{9ba8f4f563954e33b554cd3984655cee,
title = "Intravenous mycophenolate mofetil: Safety, tolerability, and pharmacokinetics",
abstract = "An intravenous (i.v.) formulation of mycophenolate mofetil (MMF; CellCept{\circledR}, Roche Pharmaceuticals, Inc., Palo Alto, CA) that will enable its administration to patients unable to tolerate oral medication is available. Two separate studies, an open-labeled pharmacokinetic (PK) study and a double-blind safety study, were performed. Within 24 h after transplant, 153 (safety study) and 45 (PK study) first or second renal transplant recipients were started on i.v. MMF 1 g Q12h or placebo (used in the safety study only, 2:1 MMF:placebo), given over 2 h via a dedicated peripheral venous catheter. In the safety study, per os (p.o.) MMF (1 g Q12h) or placebo was administered, starting within 72 h after transplant, whereas in the PK study, p.o. MMF was started on the evening of day 5. Sequential blood samples obtained on study days 5 (i.v. MMF) and 6 (p.o. MMF) before and up to 12 h after the AM dose were analyzed for mycophenolic acid (MPA) and MPA glucuronide (MPAG) concentrations by high-performance liquid chromatography. The area under the concentration curve (AUC) was calculated using the linear trapezoidal rule. The MPA AUC0-12 was higher for i.v. MMF than p.o. MMF (40.8 ± 11.4 μg.h/mL vs. 32.9 ± 15, p < 0.001). There were no other significant PK differences for plasma MPA or MPAG. In the safety study (n = 98 i.v. MMF vs. n = 55 placebo), 11 patients (11{\%}, i.v. MMF) and 4 patients (7{\%}, placebo) discontinued their use of the drug because of an adverse event (AE). Overall, AEs were similar between i.v. MMF and placebo. Injection site phlebitis (4{\%}) and thrombosis (4{\%}) were observed only with i.v. MMF. MMF i.v. 1 g twice daily (b.i.d.) should provide efficacy at least equivalent to p.o. MMF without increased toxicity, and it provides an acceptable alternative dose form in the immediate period after transplant.",
keywords = "Intravenous (i.v.), Kidney transplantation, Mycophenolate mofetil, Pharmacokinetics, Safety",
author = "Pescovitz, {Mark D.} and D. Conti and J. Dunn and T. Gonwa and P. Halloran and H. Sollinger and S. Tomlanovich and S. Weinstein and S. Inokuchi and B. Kiberd and D. Kittur and Merion, {R. M.} and D. Norman and A. Shoker and R. Wilburn and Nicholls, {A. J.} and S. Arterburn and E. Dumont",
year = "2000",
doi = "10.1034/j.1399-0012.2000.140301.x",
language = "English (US)",
volume = "14",
pages = "179--188",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Intravenous mycophenolate mofetil

T2 - Safety, tolerability, and pharmacokinetics

AU - Pescovitz, Mark D.

AU - Conti, D.

AU - Dunn, J.

AU - Gonwa, T.

AU - Halloran, P.

AU - Sollinger, H.

AU - Tomlanovich, S.

AU - Weinstein, S.

AU - Inokuchi, S.

AU - Kiberd, B.

AU - Kittur, D.

AU - Merion, R. M.

AU - Norman, D.

AU - Shoker, A.

AU - Wilburn, R.

AU - Nicholls, A. J.

AU - Arterburn, S.

AU - Dumont, E.

PY - 2000

Y1 - 2000

N2 - An intravenous (i.v.) formulation of mycophenolate mofetil (MMF; CellCept®, Roche Pharmaceuticals, Inc., Palo Alto, CA) that will enable its administration to patients unable to tolerate oral medication is available. Two separate studies, an open-labeled pharmacokinetic (PK) study and a double-blind safety study, were performed. Within 24 h after transplant, 153 (safety study) and 45 (PK study) first or second renal transplant recipients were started on i.v. MMF 1 g Q12h or placebo (used in the safety study only, 2:1 MMF:placebo), given over 2 h via a dedicated peripheral venous catheter. In the safety study, per os (p.o.) MMF (1 g Q12h) or placebo was administered, starting within 72 h after transplant, whereas in the PK study, p.o. MMF was started on the evening of day 5. Sequential blood samples obtained on study days 5 (i.v. MMF) and 6 (p.o. MMF) before and up to 12 h after the AM dose were analyzed for mycophenolic acid (MPA) and MPA glucuronide (MPAG) concentrations by high-performance liquid chromatography. The area under the concentration curve (AUC) was calculated using the linear trapezoidal rule. The MPA AUC0-12 was higher for i.v. MMF than p.o. MMF (40.8 ± 11.4 μg.h/mL vs. 32.9 ± 15, p < 0.001). There were no other significant PK differences for plasma MPA or MPAG. In the safety study (n = 98 i.v. MMF vs. n = 55 placebo), 11 patients (11%, i.v. MMF) and 4 patients (7%, placebo) discontinued their use of the drug because of an adverse event (AE). Overall, AEs were similar between i.v. MMF and placebo. Injection site phlebitis (4%) and thrombosis (4%) were observed only with i.v. MMF. MMF i.v. 1 g twice daily (b.i.d.) should provide efficacy at least equivalent to p.o. MMF without increased toxicity, and it provides an acceptable alternative dose form in the immediate period after transplant.

AB - An intravenous (i.v.) formulation of mycophenolate mofetil (MMF; CellCept®, Roche Pharmaceuticals, Inc., Palo Alto, CA) that will enable its administration to patients unable to tolerate oral medication is available. Two separate studies, an open-labeled pharmacokinetic (PK) study and a double-blind safety study, were performed. Within 24 h after transplant, 153 (safety study) and 45 (PK study) first or second renal transplant recipients were started on i.v. MMF 1 g Q12h or placebo (used in the safety study only, 2:1 MMF:placebo), given over 2 h via a dedicated peripheral venous catheter. In the safety study, per os (p.o.) MMF (1 g Q12h) or placebo was administered, starting within 72 h after transplant, whereas in the PK study, p.o. MMF was started on the evening of day 5. Sequential blood samples obtained on study days 5 (i.v. MMF) and 6 (p.o. MMF) before and up to 12 h after the AM dose were analyzed for mycophenolic acid (MPA) and MPA glucuronide (MPAG) concentrations by high-performance liquid chromatography. The area under the concentration curve (AUC) was calculated using the linear trapezoidal rule. The MPA AUC0-12 was higher for i.v. MMF than p.o. MMF (40.8 ± 11.4 μg.h/mL vs. 32.9 ± 15, p < 0.001). There were no other significant PK differences for plasma MPA or MPAG. In the safety study (n = 98 i.v. MMF vs. n = 55 placebo), 11 patients (11%, i.v. MMF) and 4 patients (7%, placebo) discontinued their use of the drug because of an adverse event (AE). Overall, AEs were similar between i.v. MMF and placebo. Injection site phlebitis (4%) and thrombosis (4%) were observed only with i.v. MMF. MMF i.v. 1 g twice daily (b.i.d.) should provide efficacy at least equivalent to p.o. MMF without increased toxicity, and it provides an acceptable alternative dose form in the immediate period after transplant.

KW - Intravenous (i.v.)

KW - Kidney transplantation

KW - Mycophenolate mofetil

KW - Pharmacokinetics

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=0034093785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034093785&partnerID=8YFLogxK

U2 - 10.1034/j.1399-0012.2000.140301.x

DO - 10.1034/j.1399-0012.2000.140301.x

M3 - Article

C2 - 10831074

AN - SCOPUS:0034093785

VL - 14

SP - 179

EP - 188

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 3

ER -